Clinical Trials Related to Pembrolizumab

Related studies linked through entity extraction aliases.

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

Status: WITHDRAWN
Phase: PHASE1

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Status: RECRUITING
Phase: PHASE1/PHASE2

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

Status: RECRUITING
Phase: PHASE1/PHASE2

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

Status: WITHDRAWN
Phase: PHASE1/PHASE2

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Status: WITHDRAWN
Phase: PHASE2

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)

Status: RECRUITING
Phase: PHASE1

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

Status: TERMINATED
Phase: PHASE1/PHASE2

A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors

Status: TERMINATED
Phase: PHASE1

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Status: RECRUITING
Phase: PHASE1

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

Status: RECRUITING
Phase: PHASE1

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Status: RECRUITING
Phase: PHASE1

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Pembrolizumab in High-risk Thyroid Cancer

Status: RECRUITING
Phase: PHASE2

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Status: RECRUITING
Phase: PHASE1

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Status: COMPLETED
Phase: N/A

Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer

Status: COMPLETED
Phase: PHASE1

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Status: RECRUITING
Phase: PHASE1/PHASE2